Sucampo CEO Peter Greenleaf Appointed Chairman of the Board of Directors
December 15 2015 - 4:15PM
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global
biopharmaceutical company, today announced that Peter Greenleaf,
Chief Executive Officer, has been appointed Chairman of the Board
of Directors, effective January 1, 2016. Mr. Greenleaf was
appointed Chief Executive Officer of Sucampo in March 2014 and was
elected to the Company’s Board at that time.
Mr. Greenleaf succeeds Dan Getman, Ph.D., who
had served as Chairman since March 2014. Dr. Getman, who has
served as a director of Sucampo since 2011, will continue on the
Board and will serve as Chairman of the nominating & corporate
governance committee of the Board.
Concurrently with Mr. Greenleaf’s appointment as
Chairman, John H. Johnson was named Lead Independent Director. Mr.
Johnson has served as a director of Sucampo since December 2014 and
was chairman of the nominating and corporate governance committee
prior to Dr. Getman’s appointment to that role.
“This appointment reflects the Board’s
confidence in Peter and underscores his accomplishments as CEO
since joining Sucampo last year,” said Mr. Johnson. “Under Peter’s
leadership, Sucampo successfully completed the acquisition of
R-Tech Ueno, solidified the Company’s revenue base and improved its
financial position, creating opportunities for continued
growth.”
Sucampo also announced that Kei Tolliver has
stepped down as a member of the Board. Ms. Tolliver,
Sucampo’s first full-time employee, previously served in several
roles with Sucampo from 1998 to 2008 and had served as a director
of Sucampo since May 2013.
Mr. Greenleaf said, “I want to thank Dan for his
contributions as Chairman, and I would like to congratulate John on
his new role. I look forward to Dan and John’s continued leadership
and guidance as members of the Board. On behalf of the Board, I
would also like to thank Kei for her service to the Company since
its inception and her recent contributions as a member of the
Board.”
About Sucampo Pharmaceuticals,
Inc.
Sucampo Pharmaceuticals, Inc. is focused on the
development and commercialization of medicines that meet major
unmet medical needs of patients worldwide. Sucampo has one marketed
product – AMITIZA – and a pipeline of product candidates in
clinical development. A global company, Sucampo is headquartered in
Rockville, Maryland, and has operations in Japan, Switzerland and
the U.K. For more information, please visit www.sucampo.com.
The Sucampo logo and the tagline, The Science of
Innovation, are registered trademarks of Sucampo AG. AMITIZA is a
registered trademark of Sucampo AG.
Follow us on Twitter (@Sucampo_Pharma). Follow
us on LinkedIn (Sucampo Pharmaceuticals).
Twitter LinkedIn
Contact:
Sucampo Pharmaceuticals, Inc.
Silvia Taylor
Senior Vice President, Investor Relations and Corporate Affairs
1-240-223-3718
staylor@sucampo.com
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From Apr 2023 to Apr 2024